Annals of the American Thoracic Society
May 9, 2025
RATIONALE: FEV and its longitudinal change are mortality risk-factors. Visit-to-visit-FEV-variation is a risk-factor for death in cystic fibrosis but has not been studied in other cohorts.
Annals of the American Thoracic Society
May 1, 2025
Some patients with interstitial lung disease (ILD) have a high mortality rate or experience acute exacerbation of ILD (AE-ILD) that results in increased mortality. Early identification of these high-risk patients and accurate prediction of the onset...
Annals of the American Thoracic Society
Feb 1, 2025
Intrapleural enzyme therapy (IET) with tissue plasminogen activator (tPA) and DNase has been shown to reduce the need for surgical intervention for complicated parapneumonic effusion/empyema (CPPE/empyema). Failure of IET may lead to delayed care an...
Annals of the American Thoracic Society
Jul 1, 2024
Randomized controlled trials of continuous positive airway pressure (CPAP) therapy for cardiovascular disease (CVD) prevention among patients with obstructive sleep apnea (OSA) have been largely neutral. However, given that OSA is a heterogeneous di...
Annals of the American Thoracic Society
Feb 1, 2024
Radiologic pattern has been shown to predict survival in patients with fibrosing interstitial lung disease. The additional prognostic value of fibrosis extent by quantitative computed tomography (CT) is unknown. We hypothesized that fibrosis extent...
Annals of the American Thoracic Society
May 1, 2023
Artificial intelligence (AI)-assisted diagnosis imparts high accuracy to chest radiography (CXR) interpretation; however, its benefit for nonradiologist physicians in detecting lung lesions on CXR remains unclear. To investigate whether AI assistan...